---
title: "Two-year LIFE-BTK data show sustained benefits of drug-eluting resorbable scaffold for below-the-knee arteries"
date: "2024-11-05T10:01:37.000Z"
publishedDate: "5 novembre 2024"
summary: "Presented today, late-breaking data from the second year of the LIFE-BTK clinical trial demonstrate the long-term effectiveness of the US Food and Drug Administration (FDA)-approved Esprit BTK everolimus-eluting resorbable scaffold system (Abbott Vascular) in patients with the most severe form of below-the-knee (BTK) peripheral arterial disease (PAD). The data show that the Esprit BTK offers [&#8230;] The post Two-year LIFE-BTK data show sustained benefits of drug-eluting resorbable scaffold for below-the-knee arteries appeared first on Cardiovascular News ."
importance: ""
sourceUrl: "https://cardiovascularnews.com/two-year-life-btk-data-show-sustained-benefits-of-drug-eluting-resorbable-scaffold-for-below-the-knee-arteries/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2024-11-05-two-year-life-btk-data-show-sustained-benefits-of-drug-eluting-resorbable-scaffold-for-below-the-knee-arteries"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/11/DeRubertis-at-VIVA-2024-1024x768.png"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/two-year-life-btk-data-show-sustained-benefits-of-drug-eluting-resorbable-scaffold-for-below-the-knee-arteries/"
---

![Two-year LIFE-BTK data show sustained benefits of drug-eluting resorbable scaffold for below-the-knee arteries](https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/11/DeRubertis-at-VIVA-2024-1024x768.png)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/two-year-life-btk-data-show-sustained-benefits-of-drug-eluting-resorbable-scaffold-for-below-the-knee-arteries/*

## L’essentiel

Presented today, late-breaking data from the second year of the LIFE-BTK clinical trial demonstrate the long-term effectiveness of the US Food and Drug Administration (FDA)-approved Esprit BTK everolimus-eluting resorbable scaffold system (Abbott Vascular) in patients with the most severe form of below-the-knee (BTK) peripheral arterial disease (PAD). The data show that the Esprit BTK offers [&#8230;] The post Two-year LIFE-BTK data show sustained benefits of drug-eluting resorbable scaffold for below-the-knee arteries appeared first on Cardiovascular News .

## Lien source

https://cardiovascularnews.com/two-year-life-btk-data-show-sustained-benefits-of-drug-eluting-resorbable-scaffold-for-below-the-knee-arteries/
